Skip to content
Yervoy(ipilimumab)
Yervoy (ipilimumab) is an antibody pharmaceutical. Ipilimumab was first approved as Yervoy on 2011-03-25. It is used to treat melanoma in the USA. It has been approved in Europe to treat colorectal neoplasms, malignant mesothelioma, melanoma, non-small-cell lung carcinoma, and renal cell carcinoma. The pharmaceutical is active against cytotoxic T-lymphocyte protein 4.
Download report
Favorite
Drugs Approved for Childhood Cancers
BMS
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
Trade Name
FDA
EMA
Yervoy
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Ipilimumab
Tradename
Proper name
Company
Number
Date
Products
YervoyipilimumabBristol-Myers Squibb CompanyN-125377 RX2011-03-25
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
yervoyBiologic Licensing Application2020-11-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
melanoma—D008545—
Agency Specific
FDA
EMA
Expiration
Code
ipilimumab, Yervoy, Bristol-Myers Squibb Company
2027-10-02Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FX: Other monoclonal antibodies and antibody drug conjugates in atc
— L01FX04: Ipilimumab
HCPCS
Code
Description
J9228
Injection, ipilimumab, 1 mg
Clinical
Clinical Trials
705 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD0085459913116213223
Renal cell carcinomaD002292172561—45
Lung neoplasmsD008175C34.9071141121
Kidney neoplasmsD007680EFO_0003865C6425—119
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8052563—185
Non-small-cell lung carcinomaD002289294012——66
Prostatic neoplasmsD011471C6112222——34
Colorectal neoplasmsD01517912152——24
GlioblastomaD005909EFO_0000515762—115
Liver neoplasmsD008113EFO_1001513C22.0982——15
SarcomaD012509791——14
Small cell lung carcinomaD055752681——12
Stomach neoplasmsD013274EFO_0003897C16362——9
Brain neoplasmsD001932EFO_0003833C71171—19
Show 11 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C251614———26
Uveal neoplasmsD014604EFO_10012301314———23
Breast neoplasmsD001943EFO_0003869C501011——120
Squamous cell carcinoma of head and neckD00007719589———16
Non-hodgkin lymphomaD008228C85.997———12
Myelodysplastic syndromesD009190D4692———11
Myeloid leukemia acuteD015470C92.0101———11
Ovarian neoplasmsD010051EFO_0003893C5678———11
Multiple myelomaD009101C90.075———10
Urologic neoplasmsD014571C64-C6885———10
Show 125 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_00003404————4
Leukemia myeloid chronic atypical bcr-abl negativeD054438C92.23————3
Hematologic neoplasmsD0193372————2
Primary myelofibrosisD055728D47.42————2
Ovarian epithelial carcinomaD0000772162————2
AnemiaD000740EFO_0004272D64.91————1
Myeloid leukemia chronic-phaseD0154661————1
ThrombocytosisD013922D75.831————1
Small cell carcinomaD0182881————1
Mycosis fungoidesD009182C84.01————1
Show 15 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIPILIMUMAB
INNipilimumab
Description
Ipilimumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)IPILIMUMAB
Structure (InChI/SMILES or Protein Sequence)
>7SU0:H,I|Fab heavy chain (PCA)VQLVESGGGVVQPGRSLRLSCAASGFTFSHYTMHWVRQAPGKGLEWVTFISYDGHNKYYADSVKGRFTISRDNSK NTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCGGHHHHHH >7SU0:L,M|Fab light chain EIVLTQSPGTLSLSPGERATLSCRASQEVGESELAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLE PEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB5TRU, 5XJ3, 6JC2, 6RP8, 7SU0, 7SU1
CAS-ID477202-00-9
RxCUI1094833
ChEMBL IDCHEMBL1789844
ChEBI ID—
PubChem CID—
DrugBankDB06186
UNII ID6T8C155666 (ChemIDplus, GSRS)
Target
Agency Approved
CTLA4
CTLA4
Organism
Homo sapiens
Gene name
CTLA4
Gene synonyms
CD152
NCBI Gene ID
1493
Protein name
cytotoxic T-lymphocyte protein 4
Protein synonyms
CD152, celiac disease 3, CTLA-4, cytotoxic T lymphocyte associated antigen 4 short spliced form, Cytotoxic T-lymphocyte-associated antigen 4, cytotoxic T-lymphocyte-associated serine esterase-4, gluten-sensitive enteropathy, insulin-dependent diabetes mellitus 12, ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
Uniprot ID
P16410
Mouse ortholog
Ctla4 (12477)
cytotoxic T-lymphocyte protein 4 (P09793)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Yervoy - Bristol Myers Squibb
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 35,612 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
199,331 adverse events reported
View more details